STOCK TITAN

Imunon (IMNN) CEO awarded stock instead of cash salary portion

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Lindborg Stacy reported acquisition or exercise transactions in this Form 4 filing.

Imunon, Inc. disclosed that President and CEO Stacy Lindborg received a grant of 4,907 shares of common stock on July 17, 2026 at $1.83 per share, issued in lieu of cash for a portion of her base salary. After this award she holds 81,629 shares directly and 778 shares indirectly through a 401(k) plan.

Positive

  • None.

Negative

  • None.
Insider Lindborg Stacy
Role President and CEO
Type Security Shares Price Value
Grant/Award Common Stock F1 4,907 $1.83 $9K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 81,629 shares (Direct); Common Stock — 778 shares (Indirect, By 401(k) Plan)
Footnotes (1)
  1. F1. Stock granted in lieu of cash for portion of base salary
Shares granted 4,907 shares Common stock granted on July 17, 2026 in lieu of cash for portion of base salary
Grant price $1.83 per share Valuation used for the 4,907-share common stock grant
Direct holdings after grant 81,629 shares Total Imunon common stock directly owned by Stacy Lindborg following the transaction
Indirect 401(k) holdings 778 shares Imunon common stock held indirectly by Stacy Lindborg through a 401(k) plan
stock granted in lieu of cash financial
"Stock granted in lieu of cash for portion of base salary"
401(k) Plan financial
"total_shares_following_transaction 778.0000, nature_of_ownership By 401(k) Plan"
A 401(k) plan is a workplace retirement account that lets employees set aside part of their pay into a tax-advantaged savings pot, often with employers adding matching contributions — like a workplace piggy bank for future income. It matters to investors because the amount people save and how employers fund these plans influence consumer spending, corporate payroll costs and the flow of money into financial markets, which can affect stock prices and company valuations.
indirect ownership financial
"ownership_type indirect, ownership_code I, nature_of_ownership By 401(k) Plan"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Imunon (IMNN) CEO Stacy Lindborg report?

Stacy Lindborg reported receiving a grant of 4,907 shares of Imunon common stock. The shares were awarded on July 17, 2026 as equity compensation, issued instead of cash for a portion of her base salary, rather than as an open-market purchase.

How many Imunon (IMNN) shares were granted to Stacy Lindborg and at what value?

She was granted 4,907 shares of Imunon common stock valued at $1.83 per share. According to the footnote, this stock was granted in lieu of cash for a portion of her base salary, reflecting equity-based compensation rather than a cash payment.

What are Stacy Lindborg’s total Imunon (IMNN) holdings after this grant?

After the grant, Stacy Lindborg directly holds 81,629 shares of Imunon common stock. She also has an additional 778 shares held indirectly through a 401(k) plan, as reported in the same insider ownership disclosure.

Was the Imunon (IMNN) CEO stock grant made under a Rule 10b5-1 trading plan?

The transaction was not indicated as being under a Rule 10b5-1 trading plan. The filing’s 10b5-1 checkbox is marked false, and the footnote describes the award simply as stock granted in lieu of cash salary.

How are some of Stacy Lindborg’s Imunon (IMNN) shares held indirectly?

In addition to direct holdings, Stacy Lindborg reports 778 Imunon shares held indirectly via a 401(k) plan. This is shown as an indirect ownership line, labeled "By 401(k) Plan," separate from her directly held common stock.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lindborg Stacy

(Last)(First)(Middle)
C/O IMUNON, INC.
997 LENOX DRIVE, SUITE 100

(Street)
LAWRENCEVILLE NEW JERSEY 08648

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/17/2026A4,907(1)A$1.8381,629D
Common Stock778IBy 401(k) Plan
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Stock granted in lieu of cash for portion of base salary
/s/ Susan Eylward, Attorney-in-Fact for Stacy Lindborg07/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)